Stratified analysis for associations between CD133 rs2240688 polymorphism (dominant for the C allele) and overal survival among non-small cell lung cancer patients recruited from Henan Provincial People’s Hospital between January 2006 and December 2014
| Variables | rs2240688 (death/patients) | MST (Months) | HR (95% CI) | Adjusted HR (95% CI)* | |
| AA | AC/CC | ||||
| Age (years) | |||||
| <65 | 254/367 | 324/411 | 20.1 vs 14.1 | 1.36 (1.16 to 1.61) | 1.44 (1.22 to 1.70) |
| ≥65 | 209/285 | 253/316 | 21.2 vs 11.9 | 1.54 (1.28 to 1.85) | 1.46 (1.21 to 1.76) |
| Sex | |||||
| Male | 249/334 | 326/390 | 18.1 vs 11.8 | 1.53 (1.30 to 1.80) | 1.45 (1.23 to 1.71) |
| Female | 214/318 | 251/337 | 23.0 vs 16.8 | 1.32 (1.10 to 1.59) | 1.45 (1.21 to 1.74) |
| Smoking status | |||||
| Non-smoker | 82/116 | 89/120 | 18.3 vs 16.8 | 1.19 (0.88 to 1.60) | 1.28 (0.94 to 1.74) |
| Former smoker | 188/278 | 241/309 | 26.0 vs 13.4 | 1.54 (1.27 to 1.86) | 1.52 (1.25 to 1.84) |
| Current smoker | 193/258 | 247/298 | 19.0 vs 11.6 | 1.43 (1.18 to 1.72) | 1.44 (1.19 to 1.74) |
| Histopathology type | |||||
| Lung adenocarcinoma | 253/377 | 313/414 | 23.0 vs 16.0 | 1.40 (1.19 to 1.66) | 1.44 (1.22 to 1.70) |
| Lung squamous cell cancer | 118/161 | 132/170 | 21.0 vs 12.0 | 1.40 (1.09 to 1.79) | 1.32 (1.03 to 1.71) |
| Others | 92/114 | 132/143 | 14.6 vs 9.0 | 1.54 (1.18 to 2.01) | 1.51 (1.14 to 2.00) |
| Stage | |||||
| I-II | 78/169 | 140/224 | 53.9 vs 18.0 | 2.09 (1.58 to 2.77) | 2.28 (1.72 to 3.03) |
| III | 217/272 | 219/256 | 19.0 vs 15.5 | 1.15 (0.95 to 1.39) | 1.17 (0.97 to 1.42) |
| IV | 168/211 | 218/247 | 13.4 vs 11.2 | 1.42 (1.16 to 1.73) | 1.43 (1.16 to 1.75) |
| Family history | |||||
| Yes | 71/102 | 80/103 | 22.2 vs 11.6 | 1.52 (1.10 to 2.09) | 1.56 (1.12 to 2.17) |
| No | 392/550 | 497/624 | 20.0 vs 13.2 | 1.42 (1.24 to 1.62) | 1.41 (1.23 to 1.61) |
| Surgery | |||||
| No | 191/232 | 274/306 | 12.3 vs 9.6 | 1.36 (1.13 to 1.64) | 1.38 (1.15 to 1.66) |
| Lobectomy | 157/210 | 179/206 | 26.0 vs 17.0 | 1.38 (1.11 to 1.71) | 1.40 (1.12 to 1.74) |
| Segmentectomy | 61/95 | 61/100 | 25.0 vs 21.6 | 1.14 (0.80 to 1.62) | 1.27 (0.87 to 1.84) |
| Wedge resection | 54/115 | 63/115 | 48.9 vs 23.4 | 1.72 (1.19 to 2.48) | 1.75 (1.20 to 2.54) |
| History of radiotherapy | |||||
| No | 196/237 | 230/266 | 15.0 vs 12.0 | 1.17 (0.97 to 1.42) | 1.24 (1.02 to 1.51) |
| Palliative therapy | 103/125 | 113/130 | 19.0 vs 16.8 | 1.19 (0.91 to 1.56) | 1.16 (0.88 to 1.53) |
| Curative intent | 164/290 | 234/331 | 31.2 vs 12.8 | 1.90 (1.55 to 2.32) | 1.90 (1.55 to 2.33) |
| Adjuvant chemotherapy | |||||
| No | 294/384 | 326/391 | 19.3 vs 16.2 | 1.23 (1.05 to 1.44) | 1.22 (1.04 to 1.43) |
| Yes | 169/268 | 251/336 | 22.7 vs 9.9 | 1.78 (1.46 to 2.16) | 1.86 (1.52 to 2.26) |
*Adjusted for age, sex, smoking status, histopathology type, stage, chemotherapy and radiotherapy.
MST, median survival time.